POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac and skeletal muscle, and maintenance of normal renal function. Sodium chloride provides sodium and chloride ions, which are essential for extracellular fluid balance and acid-base balance.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; minimal metabolism. Sodium chloride is not metabolized; excreted predominantly in urine. |
| Excretion | Primarily renal (>90% excreted by kidneys); minimal fecal (<5%) and biliary elimination. Excretion is directly dependent on glomerular filtration and tubular handling. |
| Half-life | Plasma half-life is not defined for potassium as it is tightly regulated; however, the elimination of an administered dose follows a rapid distribution phase (minutes) and slower renal clearance with an effective half-life of approximately 8–12 hours in patients with normal renal function. In oliguric states, half-life is significantly prolonged. |
| Protein binding | Potassium is not significantly bound to plasma proteins; protein binding is negligible (<5%). |
| Volume of Distribution | Approximately 0.5–0.7 L/kg, reflecting distribution primarily in extracellular fluid (total body water ~0.6 L/kg). Vd is not directly clinically used for potassium dosing, as potassium is mainly intracellular. |
| Bioavailability | Intravenous: 100%. Not administered orally as a 0.224% solution in 0.9% sodium chloride (this formulation is for IV use only). |
| Onset of Action | IV infusion: onset within minutes as potassium is rapidly distributed into extracellular fluid. Immediate effect on serum potassium levels and cardiac conduction. |
| Duration of Action | Duration of action depends on dose and renal function: after IV repletion, serum potassium elevation persists for 4–6 hours; tissue stores may require 1–2 days to replete fully. Continuous infusion maintains steady levels. |
| Molecular Weight | 74.55 |
Intravenous infusion. Typically 10-20 mEq/h, not exceeding 40 mEq/h or 200 mEq per 24 hours. Rate depends on serum potassium and clinical condition.
| Dosage form | INJECTABLE |
| Renal impairment | GFR < 30 mL/min: reduce dose by 50% and monitor serum potassium closely. GFR < 15 mL/min: avoid use or use extreme caution with continuous monitoring. |
| Liver impairment | No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances. |
| Pediatric use | IV: 0.5-1 mEq/kg per dose, max 40 mEq per dose, infused at a rate not exceeding 0.5-1 mEq/kg/h. Monitor serum potassium frequently. |
| Geriatric use | Initiate at lower end of dosing range. Monitor renal function and serum potassium closely due to age-related decline in renal function. |
| 1st trimester | Potassium chloride at this concentration is generally considered safe for maternal electrolyte replacement. Excessive potassium may cause hyperkalemia, which can affect fetal heart rate. Use only if clearly needed. |
| 2nd trimester | Similar to first trimester; normal maintenance doses are not associated with teratogenic risk. Monitor serum potassium to avoid maternal hyperkalemia. |
| 3rd trimester | Use with caution; rapid infusion may cause maternal hyperkalemia leading to fetal bradycardia. Preferred route is oral or slow IV infusion at ≤10 mEq/h. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta via active transport and diffusion. IV potassium administration may increase fetal serum potassium, but at therapeutic doses the transfer is minimal and regulated by maternal-fetal gradient. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Intravenous administration at recommended doses does not cause significant changes in milk potassium levels. Use is considered compatible with breastfeeding. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride and sodium chloride are endogenous substances. No teratogenic effects are expected at physiological concentrations. However, hyperkalemia or hypernatremia from excessive administration may cause fetal arrhythmias or electrolyte disturbances. First trimester: no increased risk of malformations. Second trimester: no specific risks. Third trimester: risk of fetal electrolyte imbalance if maternal levels are abnormal. |
| Fetal Monitoring | Monitor serum potassium, sodium, chloride, and renal function. In pregnant patients, assess fluid balance, urine output, and signs of hyperkalemia (ECG changes, muscle weakness) or hypernatremia (thirst, altered mental status). Fetal monitoring: if maternal electrolytes are abnormal, consider fetal heart rate monitoring for arrhythmias. |
| Fertility Effects | No direct effects on fertility reported. Electrolyte imbalances may indirectly affect reproductive function, but at therapeutic doses, no adverse impact on fertility. |
■ FDA Black Box Warning
No FDA boxed warning.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydrationHeat crampsConcomitant use of potassium-sparing diureticsUntreated hyperkalemia in any form
| Precautions | Use with caution in renal impairment (reduced potassium excretion may lead to hyperkalemia), Monitor serum potassium levels closely; life-threatening hyperkalemia can occur, Use with caution in patients with cardiac disease (especially if receiving digitalis), Avoid rapid infusion to prevent localized hyperkalemia and cardiac arrest, Use with caution in conditions associated with potassium retention (e.g., severe burns, Addison's disease), Extravasation may cause tissue necrosis; ensure proper IV placement |
| Food/Dietary | Avoid excessive dietary potassium intake (e.g., bananas, oranges, potatoes, salt substitutes) without medical approval. No specific food interactions for sodium chloride 0.9%. |
| Clinical Pearls | This solution provides 30 mEq/L potassium and 154 mEq/L sodium. Use with caution in renal impairment; monitor serum potassium and ECG. Do not administer undiluted; peripheral infusion may cause phlebitis. Compatible with most IV medications but avoid simultaneous blood transfusion. |
| Patient Advice | Report any pain, redness, or swelling at the IV site. · Inform your healthcare provider about any heart or kidney problems. · Do not adjust the IV rate yourself; the flow is controlled by the infusion pump. · This solution contains potassium; taking extra potassium supplements may be harmful. |
Loading safety data…